{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["75(Suppl 2)"],"submitter":["Richardson VL"],"funding":["Instituto Mexicano del Seguro Social (IMSS), Government of Mexico"],"pubmed_abstract":["Background
Beginning in March 2021, Mexico vaccinated childcare workers with a single-dose CanSino Biologics (Adv5-nCoV) coronavirus disease 2019 (COVID-19) vaccine. Although CanSino is currently approved for use in 10 Latin American, Asian, and European countries, little information is available about its vaccine effectiveness (VE).Methods
We evaluated CanSino VE within a childcare worker cohort that included 1408 childcare facilities. Participants were followed during March-December 2021 and tested through severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse-transcription polymerase chain reaction or rapid antigen test if they developed any symptom compatible with COVID-19. Vaccination status was obtained through worker registries. VE was calculated as 100"],"journal":["Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"],"pagination":["S167-S173"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9214173"],"repository":["biostudies-literature"],"pubmed_title":["Vaccine Effectiveness of CanSino (Adv5-nCoV) Coronavirus Disease 2019 (COVID-19) Vaccine Among Childcare Workers-Mexico, March-December 2021."],"pmcid":["PMC9214173"],"pubmed_authors":["Richardson VL","Lafond KE","Azziz-Baumgartner E","Gharpure R","Camacho Franco MA","Hernandez Avila M","Bautista Marquez A","Cruz Cruz V","Castro Ceronio LE","Yau TS","Martinez Valdez L"],"additional_accession":[]},"is_claimable":false,"name":"Vaccine Effectiveness of CanSino (Adv5-nCoV) Coronavirus Disease 2019 (COVID-19) Vaccine Among Childcare Workers-Mexico, March-December 2021.","description":"Background
Beginning in March 2021, Mexico vaccinated childcare workers with a single-dose CanSino Biologics (Adv5-nCoV) coronavirus disease 2019 (COVID-19) vaccine. Although CanSino is currently approved for use in 10 Latin American, Asian, and European countries, little information is available about its vaccine effectiveness (VE).Methods
We evaluated CanSino VE within a childcare worker cohort that included 1408 childcare facilities. Participants were followed during March-December 2021 and tested through severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse-transcription polymerase chain reaction or rapid antigen test if they developed any symptom compatible with COVID-19. Vaccination status was obtained through worker registries. VE was calculated as 100","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2026-03-17T15:51:17.621Z","creation":"2025-02-19T05:06:22.325Z"},"accession":"S-EPMC9214173","cross_references":{"pubmed":["35717650"],"doi":["10.1093/cid/ciac488"]}}